ATR and prostate neoplasm: As with berzosertib, the recently reported ATR inhibitor M4344 demonstrated synergistic cytotoxicity in combination with topotecan or irinotecan in established cell lines, patient-derived prostate tumor organoids, and SCLC tumor xenograft models (48).